Treatment of adult acute lymphoblastic leukemia according to GMALL 07/ 2003 study protocol in the Czech Republic – the first experience

Česká verzia

Authors: F. Folber ¹; C. Šálek ²; M. Doubek ¹; J. Soukupová Maaloufová ²; T. Valová ³; J. Trka ³; N. Gökbuget ⁴; J. Vydra ⁵; T. Kozák ⁵; J. M. Horáček ⁶; P. Žák ⁶; P. Cetkovský ²; D. Hoelzer ⁴; J. Mayer ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jiří Vorlíček, CSc. 2Klinický úsek Ústavu hematologie a krevní transfuze Praha, přednosta doc. MU Dr. Petr Cetkovský, Ph. D. 3Childhood leukaemia ¹
Published in the journal: Vnitř Lék 2010; 56(3): 176-182
Category: Original Contributions

Summary

Introduction:
We present two years’ experience in the treatment of adult acute lymphoblastic leukemia (ALL) according to the German GMALL 07/ 2003 study protocol at CELL (Czech leukemia study group – for life) hematological centers in the Czech Republic.

Methods:
A total number of 37 patients were included in this analysis. We evaluated complete remission and molecular remission rate, incidence of relapse, patients’ status at the end of the follow‑up period, incidence of chemotherapy‑related adverse events and causes of death. A statistical analysis of risk factors affecting survival was carried out.

Results:
Complete remission was achieved in 36 (97%) patients and molecular remission in 16 (62%) of 26 evaluable patients. Disease relapse occurred in 5 (14%) patients. At the end of the follow‑up period with a median of 261 days, 28 (76%) patients were alive in complete remission, one (3%) with relapsed disease and 8 (22%) dead. Treatment toxicity resulted in death in 5 cases, relapse or progression of ALL in 3 patients. Adverse events most often followed consolidation I, induction phase I, consolidation II and induction phase II. Infectious complications in the context of febrile neutropenia, GIT mucositis and side effects of PEG‑ asparaginase were the most common adverse events observed. The toxicity of allogeneic transplantation was not unexpected, four (25%) patients died after transplantation. Two‑year progression‑free and overall survival were 66% and 70%, respectively. High risk ALL, age over 35 years, CNS infiltration, disease relapse and permanent minimal residual disease were identified as the major adverse prognostic risk factors. Practical experiences and possible pitfalls of the protocol are described in the discussion.

Conclusion:
Our initial impression is promising. The treatment is feasible, the results very good and the toxicity acceptable. Patients at high risk should be headed to allogeneic transplantation, since the results of consolidation chemotherapy alone are very poor in this group. We believe that this study protocol could become a standard adult acute lymphoblastic leukemia treatment in the Czech Republic.

Key words:
acute lymphoblastic leukemia – adults – chemotherapy – hematopoietic stem cell transplantation – adverse events – risk factors – GMALL 07/ 2003 trial

Zdroje

1. Fielding AK, Rowe JM, Richards SM et al. Prospective outcome data on 267 unselected adult patients with Philadelphia‑ chromosome positive acute lymphoblastic leukaemia confirms superiority of allogeneic transplant over chemotherapy in the pre‑imatinib era: Results from the international ALL trial MRC UKALLXII/ ECOG2993. Blood 2009; 113: 4489– 4496.

2. Rowe JM. Optimal management of adults with ALL. Br J Haematol 2009; 144: 468– 483.

3. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009; 46: 64– 75.

4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166– 178.

5. Huguet F, Leguay T, Raffoux E et al. Pediatric‑ inspired therapy in adults with Philadelphia chromosome‑ negative acute lymphoblastic leukemia: the GRAALL‑ 2003 study. J Clin Oncol 2009; 27: 911– 918.

6. Barry E, DeAngelo DJ, Neuberg D et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana‑ Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25: 813– 819.

7. Hoelzer D, Thiel E, Löffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123– 131.

8. De Labarthe A, Rousselot P, Huguet‑ Rigal Fet al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome‑ positive acute lymphoblastic leukemia: results of the GRAAPH‑ 2003 study. Blood 2007; 109: 1408– 1413.

9. Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program 2006: 142– 146.

10. van der Velden VH, Cazzaniga G, Schrauder A et al. European Study Group on MRD detection in ALL (ESG‑ MRD‑ ALL). Analysis of minimal residual disease by Ig/ TCR gene rearrangements: guidelines for interpretation of real‑ time quantitative PCR data. Leukemia 2007; 21: 604– 611.

11. Doubek M, Mayer J, Kořístek Z et al. Terapie akutní lymfoblastické leukemie dospělých kombinací sedmi chemoterapeutik v indukční léčbě, intenzivní konsolidací s autologní transplatací kmenových buněk krvetvorby nebo bez ní a s následnou udržovací léčbou: zkušenosti jednoho centra. Čas Lék Česk 2002; 141: 122– 126.

12. Doubek M, Folber F, Koristek Z et al. Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion. Ann Hematol 2009; 88: 881– 887.

13. Linker C, Damon L, Ries C et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464– 2471.

14. Gökbuget N, Hoelzer D, Arnold R et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307– 1325.

15. Douer D. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 2008; 21: 647– 658.

16. Yanada M, Matsuo K, Suzuki T et al. Allogeneic hematopoietic stem Cell transplantation as part of postremission therapy improves survival for adult patients with high‑risk acute lymphoblastic leukemia. Cancer 2006; 106: 2657– 2663.

17. Gökbuget N, Raff R, Brügge‑ Mann M et al. Risk/ MRD adapted GMALL trials in adult ALL. Ann Hematol 2004; 83 (Suppl 1): S129– S131.

18. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006: 133– 141.